AMERICAN BIOMED, Minimally Invasive Technology (ABMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: greg Benfield who wrote (2290)	12/11/1998 3:33:00 PM
From: Jeffrey L. Henken	Read Replies (1) of 2887

American BioMed markets a series of patent protected 100% silicone catheters. These catheters are used in the removal of thrombi(blood clots) and the delivery of medications or fluids in precise amounts. americanbiomed.com While these catheters are superior in many respects to those manufactured by competitors investors should realize that American BioMed is never going to become a market leader on it's own in any of the markets in which these catheters compete. The most exciting of these catheters is the Ahn Thrombectomy Catheter. The unique dual balloon design is patented and is gaining market share. One possibility for the future here would be a combined dual balloon drug delivery catheter. Such a design could use a thrombolitic agent(clot dissolving drug) in combination with the improved thrombectomy design. americanbiomed.com I know many of us have been disappointed in American BioMed's ability to grow sales despite putting together a world class distribution system. CE Mark approval came so late in the last quarter that in my opinion it was impossible for American BioMed to really fully meet demand for their products. americanbiomed.com Do I expect a profit from American BioMed's catheter line at any point in the future? Not really, not anymore. Despite what some people might like us to believe it is really the distribution system that is important here not the possible chance of profits selling catheters. This distribution system will really pay off when American BioMed begins to sell FDA approved OmniCaths and Guidewire Microfilters. American BioMed needs to fund the development of these technologies. I would like to see prototypes of the Omnifilter and the OmniStent technology finished as soon as possible. There has been quite a bit of discussion of the value of American BioMed's patents over the past few months. They are extremely valuable, in my opinion, but until the medical community at large can hold a prototype of one of these products in their hands the value of those patents is subject to a high degree of speculation. On the plus side American BioMed is very close indeed to being able to show off a finished prototype of these technologies. The only thing that stands between that reality is simply finding adequate funding. American BioMed still has a number of options to make this happen and I am certain they are being fully explored. One method might be the sale of non essential technologies. To me I would think that would include anything short of the Omnifilter technology. Lets say for instance that American BioMed was to sell it's catheter line. We have often discussed how much better American BioMed's products would sell if they were part of a large multinational medical company's product line. If these silicone catheters were bundled properly they would sell at significantly higher levels. The money derived from such a sale could be funneled directly into R&D by American BioMed. In many ways ABMI shareholders would be better off if American BioMed did not have an actual product line that it was actively marketing. Should they sell the catheter line? Perhaps. However I would hesitate to say sell it unless American BioMed was adequately compensated. And there in lies the rub for all investors who question the reasons why some or all of American BioMed has not been acquired to date. None of us know what discussions have taken place or how serious they may have been. Personally I believe there have been discussions in the past and that there will be more in the future. If American BioMed is receive a bid for the entire company at a valuation which will fully reflect the revenue potential of a product like the Omnifilter then the prototype must be finished first. americanbiomed.com I am not opposed to the sale of any product or product line in the company to see this happen other than the Omnifilter itself. This of course is pure conjecture. I believe that the fund raising efforts at American BioMed continue on a day to day basis and that the probability of good news along those lines is exceptionally high. Regards, Jeff

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next